Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Spinal cord injury · Other
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
RatSpinal cord injuryUnspecifiedSprague-DawleyFemale
Model: Acute traumatic spinal cord injury
DMOG raised HIF-1alpha expression, reduced apoptotic protein expression, enhanced axonal regeneration through microtubule stabilisation and improved functional recovery; the benefit was abolished by inhibition of HIF-1alpha or autophagy.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
MouseOtherC57BL/6MaleIntraperitoneal injection
Model: Acute lung injury induced by intratracheal instillation of Fas ligand
Dimethyloxalylglycine increased HIF-1 alpha and decreased Fas expression in lung tissue, attenuated caspase-3 activation and apoptotic cell death, reduced the increase in alveolar permeability after intratracheal Fas ligand, and lessened inflammatory responses and histopathological changes. The ant…
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
